Literature DB >> 18568141

Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.

Mona Munteanu1, Vlad Ratziu, Rachel Morra, Djamila Messous, Francoise Imbert-Bismut, Thierry Poynard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18568141

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN： 1841-8724            Impact factor:   2.008


× No keyword cloud information.
  17 in total

Review 1.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 2.  Nonalcoholic fatty liver disease.

Authors:  Sandra K Erickson
Journal:  J Lipid Res       Date:  2008-12-12       Impact factor: 5.922

Review 3.  NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?

Authors:  Shivaram P Singh; Rakesh K Barik
Journal:  J Clin Exp Hepatol       Date:  2019-09-21

4.  Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.

Authors:  Anil Arora; Praveen Sharma
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

5.  Urinary procollagen III aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist.

Authors:  Balsam El Ghoul; Tarek Squalli; Aude Servais; Caroline Elie; Vannary Meas-Yedid; Christine Trivint; Jill Vanmassenhove; Jean-Pierre Grünfeld; Jean-Christophe Olivo-Marin; Eric Thervet; Laure-Hélène Noël; Dominique Prié; Fadi Fakhouri
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-14       Impact factor: 8.237

6.  SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients.

Authors:  Shizhen Qin; Yong Zhou; Anna S Lok; Alex Tsodikov; Xiaowei Yan; Li Gray; Min Yuan; Robert L Moritz; David Galas; Gilbert S Omenn; Leroy Hood
Journal:  Proteomics       Date:  2012-04       Impact factor: 3.984

7.  Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study.

Authors:  Tatiana Codjia; Lionel Rebibo; Arnaud François; Carole Lagnel; Emmanuel Huet; Soumeya Bekri; François Pattou; Jean-Marc Régimbeau; Lilian Schwarz
Journal:  Obes Surg       Date:  2021-04-12       Impact factor: 4.129

8.  Global hepatitis C elimination: history, evolution, revolutionary changes and barriers to overcome.

Authors:  Carmen Nicoleta Oancea; Anca Elena Butaru; Costin Teodor Streba; Daniel Pirici; Ion Rogoveanu; Mihai Mircea Diculescu; Dan Ionuţ Gheonea
Journal:  Rom J Morphol Embryol       Date:  2020 Jul-Sep       Impact factor: 1.033

9.  EPHX1 mutations cause a lipoatrophic diabetes syndrome due to impaired epoxide hydrolysis and increased cellular senescence.

Authors:  Jeremie Gautheron; Christophe Morisseau; Wendy K Chung; Jamila Zammouri; Martine Auclair; Genevieve Baujat; Emilie Capel; Celia Moulin; Yuxin Wang; Jun Yang; Bruce D Hammock; Barbara Cerame; Franck Phan; Bruno Fève; Corinne Vigouroux; Fabrizio Andreelli; Isabelle Jeru
Journal:  Elife       Date:  2021-08-03       Impact factor: 8.140

10.  Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study.

Authors:  Shuhei Fukunaga; Dan Nakano; Takumi Kawaguchi; Mohammed Eslam; Akihiro Ouchi; Tsutomu Nagata; Hidefumi Kuroki; Hidemichi Kawata; Hirohiko Abe; Ryuichi Nouno; Koutaro Kawaguchi; Jacob George; Keiichi Mitsuyama; Takuji Torimura
Journal:  Int J Mol Sci       Date:  2021-05-22       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.